SBRT, proton beam therapy use increasing for prostate CA

June 13, 2016

(HealthDay)—For men with prostate cancer, the use of stereotactic body radiotherapy (SBRT) and proton beam therapy increased from 2004 to 2011, according to a study published online May 25 in Cancer.

Joshua A. Halpern, M.D., from the Weill Cornell Medical College in New York City, and colleagues compared temporal trends and outcomes for men with undergoing SBRT, brachytherapy, intensity-modulated radiotherapy (IMRT), and therapy (542; 9,647; 23,408; and 800 men, respectively) from 2004 to 2011.

The researchers found that the use of SBRT and proton beam therapy increased significantly (P < 0.001), while there was a decrease in brachytherapy use (P < 0.001). Compared with those treated with IMRT and proton beam therapy, a higher percentage of patients treated with SBRT and brachytherapy had low-grade (Gleason score, ≤6 versus ≥7) (35.2 and 49.6 percent versus 54.0 and 64.2 percent, respectively; P < 0.001). Compared with brachytherapy and IMRT, SBRT correlated with equivalent gastrointestinal toxicity, but with more erectile dysfunction at two-year follow-up (P < 0.001). SBRT correlated with more urinary incontinence than IMRT and proton beam therapy. The median costs were $27,154 for SBRT, $17,183 for , $37,090 for IMRT, and $54,706 for proton beam therapy (P < 0.001).

"Despite men of lower disease stage undergoing SBRT, SBRT was found to be associated with greater toxicity but lower health care costs compared with IMRT and ," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Explore further: New prostate cancer treatment convenient, less expensive, but may be riskier

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

New prostate cancer treatment convenient, less expensive, but may be riskier

March 10, 2014
A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers—a higher rate of urinary complications.

Proton therapy has advantages over IMRT for advanced head and neck cancers

July 1, 2014
A new study by radiation oncologists at Mayo Clinic comparing the world's literature on outcomes of proton beam therapy in the treatment of a variety of advanced head and neck cancers of the skull base compared to intensity ...

Despite hype, costly prostate cancer treatment offers little relief from side effects

December 13, 2012
Prostate cancer patients receiving the costly treatment known as proton radiotherapy experienced minimal relief from side effects such as incontinence and erectile dysfunction, compared to patients undergoing a standard radiation ...

Research shows 98 percent cure rate for prostate cancer using SBRT

April 18, 2016
A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold ...

Proton therapy effective prostate cancer treatment

January 5, 2012
Proton therapy, a type of external beam radiation therapy, is a safe and effective treatment for prostate cancer, according to two new studies published in the January issue of the International Journal of Radiation Oncology•Biology•Physics ...

Study examines adverse effects among different radiation therapies for prostate cancer

April 17, 2012
In an analysis of three different types of radiation therapy used to treat localized prostate cancer, compared with conformal radiation therapy, intensity-modulated radiation therapy (IMRT) was associated with fewer diagnoses ...

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.